Guggenheim started coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The firm issued a neutral rating on the biotechnology company’s stock.

A number of other equities analysts also recently weighed in on the stock. Canaccord Genuity restated a buy rating and set a $70.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, March 13th. Jefferies Group boosted their target price on shares of Atara Biotherapeutics from $30.00 to $46.00 and gave the stock a buy rating in a report on Monday, March 5th. BidaskClub downgraded shares of Atara Biotherapeutics from a strong-buy rating to a buy rating in a report on Thursday, March 1st. JMP Securities downgraded shares of Atara Biotherapeutics from an outperform rating to a market perform rating in a report on Wednesday, February 28th. Finally, Zacks Investment Research upgraded shares of Atara Biotherapeutics from a sell rating to a hold rating in a report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of $33.80.

How to Become a New Pot Stock Millionaire

ATRA stock opened at $41.90 on Thursday. The firm has a market cap of $1,626.81, a price-to-earnings ratio of -10.50 and a beta of 2.59. Atara Biotherapeutics has a fifty-two week low of $11.80 and a fifty-two week high of $49.90.

In other Atara Biotherapeutics news, EVP Heather D. Turner sold 12,214 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $38.01, for a total value of $464,254.14. Following the transaction, the executive vice president now directly owns 77,112 shares in the company, valued at $2,931,027.12. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 22,200 shares of the company’s stock in a transaction on Friday, December 29th. The shares were sold at an average price of $18.29, for a total transaction of $406,038.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 343,797 shares of company stock worth $10,682,763. Corporate insiders own 16.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC acquired a new position in shares of Atara Biotherapeutics in the fourth quarter valued at $217,000. Nexthera Capital LP bought a new stake in shares of Atara Biotherapeutics in the fourth quarter valued at about $5,188,000. Raymond James & Associates boosted its position in shares of Atara Biotherapeutics by 7.3% in the fourth quarter. Raymond James & Associates now owns 25,325 shares of the biotechnology company’s stock valued at $458,000 after acquiring an additional 1,719 shares during the period. Bridger Management LLC boosted its position in shares of Atara Biotherapeutics by 57.3% in the fourth quarter. Bridger Management LLC now owns 2,598,599 shares of the biotechnology company’s stock valued at $47,035,000 after acquiring an additional 946,086 shares during the period. Finally, California State Teachers Retirement System boosted its position in shares of Atara Biotherapeutics by 4.6% in the fourth quarter. California State Teachers Retirement System now owns 42,159 shares of the biotechnology company’s stock valued at $763,000 after acquiring an additional 1,836 shares during the period. Hedge funds and other institutional investors own 76.88% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Atara Biotherapeutics (ATRA) Now Covered by Analysts at Guggenheim” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.watchlistnews.com/atara-biotherapeutics-atra-now-covered-by-analysts-at-guggenheim/1944838.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.